Covaxin is 81 per cent effective in preventing Covid and can work against the UK variant of the virus, Bharat Biotech said Wednesday as it revealed Phase III trial results for a vaccine that was cleared in January amid concerns over its safety and efficacy.

"... Covaxin demonstrated 81 per cent interim efficacy in preventing COVID-19 in those without prior infection after the second dose," Bharat Biotech said in its statement.

India's indigenously developed vaccine against coronavirus COVAXIN has demonstrated an interim vaccine efficacy of 81 per cent in its Phase 3 clinical trial. The trials involved 25,800 subjects, the largest ever conducted in India, in partnership with ICMR, informed vaccine maker Bharat Biotech.